Background. We recently reported that durable chimerism can be safely established in mismatched kidney recipients through nonmyeloablative conditioning followed by infusion of a facilitating cell (FC)-based hematopoietic stem cell transplantation termed FCRx. Here we provide intermediate-term follow-up on this phase II trial. Methods. Fifteen human leukocyte antigenYmismatched living donor renal transplant recipients underwent lowintensity conditioning (fludarabine, cyclophosphamide, 200 cGy TBI), received a living donor kidney transplant on day 0, then infusion of cryopreserved FCRx on day +1. Maintenance immunosuppression, consisting of tacrolimus and mycophenolate, was weaned over 1 year. Results. All but one patient demonstrated peripheral blood macrochimerism after transplantation. Engraftment failure occurred in a highly sensitized (panel reactive antibody [PRA] of 52%) recipient. Chimerism was lost in three patients at 2, 3, and 6 months after transplantation. Two of these subjects had received either a reduced cell dose or incomplete conditioning; the other two had PRA greater than 20%. All demonstrated donor-specific hyporesponsiveness and were weaned from full-dose immunosuppression. Complete immunosuppression withdrawal at 1 year after transplantation was successful in all patients with durable chimerism. There has been no graft-versushost disease or engraftment syndrome. Renal transplantation loss occurred in one patient who developed sepsis following an atypical viral infection. Two subjects with only transient chimerism demonstrated subclinical rejection on protocol biopsy despite donor-specific hyporesponsiveness. Conclusions. Low-intensity conditioning plus FCRx safely achieved durable chimerism in mismatched allograft recipients. Sensitization represents an obstacle to successful induction of chimerism. Sustained T-cell chimerism is a more robust biomarker of tolerance than donor-specific hyporeactivity.
T he toxicity of immunosuppressive agents that remain the current mainstay of solid organ transplantation has prompted investigators to pursue the induction of donorspecific tolerance. It has been known since the early reports of Owen in 1945 (1) and Billingham et al. in 1953 (2) that chimerism induces tolerance to organ and tissue transplants. Owen observed that genetically disparate ''freemartin'' cattle twins sharing a common placenta were red blood cell chimeras, suggesting that each was reciprocally tolerant to the other sibling as evidenced by persistent chimerism after birth. Billingham, Brent, and Medawar extended these findings to demonstrate that infusion of hematopoietic-derived cells into newborn mice resulted in chimerism and was associated with acceptance of donor skin grafts. In the ensuing years, significant effort was focused on overcoming obstacles preventing this approach from successful translation to the clinic: graft-versus-host disease (GVHD), the requirement for human leukocyte antigen (HLA)Ymatched bone marrow donors, and the toxicity of myeloablative conditioning.
We have developed a nonmyeloablative reducedintensity conditioning approach to establish high levels of donor chimerism without GVHD or engraftment syndrome in recipients of combined kidney and hematopoietic stem cell transplants (HSCT) (3) . We recently reported the outcomes on the first eight subjects enrolled who were at least 1 year after transplantation. Five of six recipients transplanted with the optimum facilitating cell or HSCT product (FCRx) and who received the full reduced-intensity conditioning regimen demonstrated durable whole-blood and T-cell chimerism, and were successfully weaned completely off immunosuppression. The other chimeric subject developed viral sepsis at 3 months following transplantation, lost his kidney to vascular thrombosis, and was subsequently successfully retransplanted. No patient developed GVHD or engraftment syndrome. We now present an interim followup for 15 subjects currently enrolled and transplanted. We have prospectively evaluated functional assays of donorspecific hyporesponsiveness (DSH), comparing durably chimeric recipients to those with transient macrochimerism and the one subject who failed FCRx engraftment in order to identify potential disparities in biomarkers to predict the ability to reduce or successfully discontinue immunosuppression. We report here that mixed lymphocyte reaction proliferative (MLR) and cytotoxicity (CML) assays were not reliable predictive biomarkers, as two subjects who exhibited transient macrochimerism had evidence of subclinical rejection on protocol biopsy at the time they exhibited DSH in vitro. The most predictive endpoint for tolerance was durable T-cell and whole-blood macrochimerism.
RESULTS

Patient Demographics
A total of 17 subjects have been enrolled, and 15 have received transplants in this phase II FDA regulated study (IDE 13947). They ranged in age from 18 to 60 years. All subjects were HLA-disparate from their living kidney or HSCT donors, ranging from five of six matched related to zero of six matched unrelated. The patient demographics are shown in Table 1 . Subject #13 developed de novo donorspecific antibody just prior to conditioning and did not undergo transplantation as part of our study. Subject #16 developed positive serologies for coccidiodes (residing in a high-risk endemic area) after enrollment but also prior to conditioning and is undergoing antifungal therapy.
Chimerism Testing and Outcomes
Subjects have segregated into different categories with respect to observed patterns of donor stem cell chimerism. Nine patients developed high level (990%) donor wholeblood and T-cell chimerism beginning at 1 month after transplantation. This chimerism has been durable in all but one patient (NW2) who developed an atypical viral infection at 3 months after transplantation accompanied by bone marrow failure. Despite successful recovery after infusion of stored autologous stem cells, he developed intercurrent sepsis which contributed to kidney allograft loss and loss of chimerism; this patient has successfully undergone retransplantation with a living donor kidney and currently has normal renal function. Six of eight patients with high-level donor chimerism have been fully withdrawn from immunosuppression without loss of engraftment. The remaining two have undergone successful weaning to tacrolimus monotherapy with planned full withdrawal at 1 year.
Transient donor chimerism lasting several months was observed in three subjects. Two (NW1 and NW4) received an FCRx with a reduced cell dose. In NW1, technical issues with FCRx processing of the donor leukapheresis product required a subsequent iliac crest bone marrow harvest to derive the FCRx. In addition, no posttransplantation dose of cyclophosphamide conditioning was given. In subject NW4, a deliberately reduced FCRx dose was used in response to the development of a generalized body rash concerning GVHD in the subject (NW3) who has previously undergone transplantation. As skin biopsy results were pending at the time of product infusion for NW4, we elected to reduce the FCRx cell dose infused per clinical trial design; the biopsy was consistent with bactrim photosensitivity, not GVHD. The third transiently chimeric subject (NW11) was notable for being highly sensitized, with a historic maximum HLA class I panel reactive antibody (PRA) of 64%, and an actual PRA of 33% at the time of transplantation (Table 1) .
Two subjects (NW12 and NW17) have exhibited a picture of more sustained, mixed chimerism. In NW12, initial whole blood chimerism at 1 month of 77% was detected, but no measurable T-cell chimerism was present. A gradual loss of whole-blood chimerism occurred over the next 9 months. Maintenance immunosuppression was weaned to tacrolimus monotherapy at 6 months as this subject exhibited DSH, had not developed donor specific antibody, showed measurable donor chimerism, and had normal protocol kidney biopsy. Of interest, low level (8%) wholeblood and T-cell chimerism re-emerged at 1 year after transplantation. Further weaning of immunosuppression is pending future demonstration of stable mixed chimerism, as the loss of measurable chimerism in other subjects (as discussed below) has been predictive of the development of subclinical allograft rejection. In NW17, mixed whole-blood (87%) and T-cell (48%) donor chimerism was initially established, and has been stable for the first 3 months of posttransplantation follow-up.
Complete failure of donor stem cell engraftment has occurred in only one subject (NW9). This was the recipient of a completely HLA-mismatched, living unrelated stem cell/kidney allograft. This subject was highly sensitized at the time of transplantation (class I PRA of 52%). This patient developed tacrolimus-induced hemolytic uremic syndrome early after transplantation requiring conversion to sirolimus. At 6 months, he had a normal protocol biopsy and no evidence of donor specific antibody, which prompted weaning of immunosuppression to sirolimus monotherapy. At 1 year after transplantation, he presented with new onset proteinuria and his kidney allograft biopsy showed evidence of recurrent IgA nephropathy. In vitro DSH was no longer present. He has been treated with a course of oral corticosteroids and maintained on sirolimus for maintenance immunosuppression with evidence of stable renal allograft function.
Clinical Course: Cytopenias and Infections
All subjects were discharged on postoperative day 2 to a clinical research unit and thereafter managed as outpatients. Patients experienced an expected nadir period associated with conditioning, with an absolute neutrophil count (ANC) less than 500 cells/HL lasting for a mean of 10 days (range 2Y14 days) and thrombocytopenia (platelet count of G50,000/HL) lasting for a mean of 12 days (range 0Y21 days). Cytopenias were managed with neutropenic precautions, administration of granulocyte colony stimulating factor, and platelet transfusions for a platelet count of less than 20,000. No cytomegalovirus infections have occurred. Three subjects developed single dermatome herpes zoster while still on conventional immunosuppression. No herpesvirus reactivations have occurred in patients taken off of immunosuppression. Additional significant infections have included histoplasmosis in one subject (NW14) at 5 months after transplantation; this patient, who resides in a high-risk endemic area, has responded to appropriate antifungal therapy. An additional subject (NW12) developed persistent BK virus viremia at more than 1 year after transplantation in the absence of allograft dysfunction; viral titers have gradually improved with reduction of tacrolimus-based immunosuppression. Currently, 10 of the 14 subjects who underwent transplantation and are remaining in the study (and 10 of the 12 subjects who received the optimal product and both doses of cyclophosphamide) exhibit durable chimerism at the time of this publication. None of the chimeric subjects have developed anti-donor antibody or disease recurrence after transplantation (Table 2) . No GVHD or engraftment syndrome has been observed. Of the transiently chimeric subjects one has developed recurrent membranous (NW1) and one recurrent IgA nephropathy (NW9).
In Vitro Assays of DSH Alone do not Correlate With Donor-Specific Tolerance
Our initial endpoints for tapering of immunosuppression included DSH in vitro or durable chimerism. However, as the study has progressed, in light of findings described below, we have elected to rely only on T-cell and wholeblood chimerism for the complete withdrawal of immunosuppression. The most evaluable time points for comparison were at 6 months (all subjects have had mycophenolate mofetil [MMF] discontinued) and 12 months.
In vitro proliferative and cytotoxic assays (MLR and CML) were performed at selected time points on all subjects. Recipients who developed durable high-level donor chimerism were reproducibly tolerant to their donor by MLR and CML. In addition, these ''fully'' chimeric subjects failed to respond to archived pretransplantation recipient cells in an MLR, consistent with the absence of clinical acute or chronic GVHD. In contrast, peripheral blood mononuclear cells obtained from the original stem cell/kidney donor showed robust proliferation in response to recipient stimulators (data not shown). Protocol biopsies at 6, 12, and 24 months after transplantation showed no evidence of rejection in all durably chimeric subjects (data not shown).
Recipients who exhibited transient donor chimerism in peripheral blood also demonstrated DSH, even after loss of chimerism. However, in vitro hyporesponsiveness did not predict histologic findings on protocol biopsy. The most representative of this is subject NW4. At 6 months, after gradual loss of detectable peripheral blood chimerism (Fig. 1) , MLR and CML assays and a protocol biopsy were performed (Figs. 2 and 3A) . Evidence of DSH, combined with normal allograft histology, led to the discontinuation of MMF. Repeat testing for DSH at 9 months showed persistent hyporeactivity (Fig. 2B ) and led to tapering of tacrolimus monotherapy. Despite evidence for DSH in MLR ( Fig. 2A) and CML assays, which persisted up to 18 months (Fig. 2C and D) , protocol biopsy at 12 months demonstrated a mononuclear cell infiltrate and inflammation consistent with subclinical Banff 1A rejection (Fig. 3B) . This was treated with intravenous corticosteroids, increasing tacrolimus dosing to therapeutic range and allowing the infiltrates to be completely resolved. At 24 months after transplantation, anti-donor reactivity developed in MLR (Fig. 2E) . A second subject (NW11) who had transient chimerism exhibited similar subclinical Banff 1A infiltrates on his 6-month protocol biopsy despite stable renal function and coincident DSH in vitro that responded to antirejection therapy (data not shown). Notably, there has been no evidence for rejection or fibrosis in any of the subjects with durable chimerism. A representative series of protocol biopsies at implantation (Fig. 3C ), 12 months (Fig. 3D) , and 24 months after transplantation and 1 year off all immunosuppression (Fig. 3E) is shown for subject 3.
DISCUSSION
The definition of tolerance has had numerous interpretations and defined criteria. Organ transplant recipients who have been successfully weaned from immunosuppression and have maintained stable graft function for 1 year or more are referred to as functionally or operationally tolerant (4, 5) . Although up to 20% of liver transplant recipients may be successfully withdrawn from immunosuppression (5Y7), operational tolerance to renal allografts FIGURE 3. Representative hematoxylin-eosin stained sections (magnification Â10) of kidney transplant biopsy at 6 months (A) and 1 year (B) after transplantation from subject NW4. Image A shows no acute or chronic rejection, minimal tubular atrophy, and minimal interstitial fibrosis. Image B shows Banff 1A rejection, with interstitial inflammation and lymphocytic infiltration associated with tubulitis. In contrast, all protocol biopsies on subjects with high levels of donor chimerism have been normal at all times tested. Periodic acid-Schiff staining (magnification Â20) of renal allograft from representative subject (#3) with stable donor chimerism and donor-specific tolerance (CYE). Implantation biopsy at time of live donor nephrectomy (C). One year after stem cell or kidney transplantation (D). Two years after FCRx/kidney transplantation, 1 year off all immunosuppression (E).
appears to be much less frequent (8, 9) . In all of these studies, a predictive biomarker for success versus failure in weaning immunosuppression has not been reliably identified and validated so as to be used as a tool to discontinue immunosuppression. As a result, the subjects who fail immunosuppression weaning experience rejection episodes resulting in re-initiation of conventional immunosuppression after antirejection therapy. Moreover, it is currently not known whether they will experience compromised longterm graft survival.
Historically, MLR and CML assays have been considered gold standard tests for donor-specific tolerance. However, our own recent experience and that reported by the Massachusetts General Hospital (MGH) group (10Y13) would suggest that, in the absence of macrochimerism, these tests are not uniformly reliable. In our own study, subjects exhibiting transient chimerism after transplantation were unresponsive to their donors by MLR and CML assays, sometimes for up to 18 months. However, protocol biopsies revealed cellular infiltrates and inflammation indicating subclinical rejection requiring treatment and an increase in maintenance immunosuppression. This contrasts sharply with the histologic appearance of 1-year and 2-year protocol biopsies from the durably chimeric subjects, which are completely free of cellular infiltrates or manifestations of chronic rejection. Notably, durably chimeric subjects have had normal-appearing biopsies. This contrasts sharply with nonchimeric subjects who electively discontinued immunosuppression where the majority experienced severe rejection (14) . Similarly, the MGH kidney/HSCT tolerance study, in which there was only transient microchimerism for less than 21 days, reported DSH in their nonchimeric subjects, some of which went on to experience rejection episodes (11) . Notably, 3 of 10 subjects enrolled in the MGH study experienced graft loss. One of these three subjects developed a viral infection 7 weeks after discontinuation of immunosuppression and experienced severe acute rejection and subsequent graft loss (15) . Taken together, these findings suggest that when macrochimerism is present, subjects are tolerant to their donors, but in the absence of chimerism, a tolerant profile in MLR and CML is not always predictive of success in weaning immunosuppression without rejection episodes. The MGH group attributed the persistence of donor-specific tolerance following loss of chimerism to evolution from central tolerance to regulation in part mediated by antigen from the kidney allograft itself (12, 16) . In light of the fact that infusion of donor bone marrow into unconditioned organ transplant recipients reduced the occurrence of chronic rejection (17Y19), bone marrow itself may have immunoregulatory properties. Alternatively, it is possible that the presence of transient chimerism induces clonal deletion and that replacement of those clones is delayed after loss of the chimerism. The delayed immune recovery reported by Hakim et al., in subjects undergoing chemotherapy for malignancy, would support this hypothesis (20) . As a result of these findings, we have elected to maintain our nonchimeric recipients on low-dose tacrolimus or sirolimus monotherapy indefinitely rather than discontinue immunosuppression and risk rejection.
Production of donor T cells has been used as a biomarker of graft durability in HSCT (21) . In the present study, this metric has successfully translated to predict stable graft function and absence of rejection to date. Obviously, more patients and longer follow-up will be required to confirm this observation. The dichotomy between chimerism and tolerance was first reported when knockout mice were used as donors for bone marrow. It was shown that T cells and antigen-presenting cells were necessary for tolerance induction (22Y24). In spite of chimerism, donorspecific skin transplants were rejected. Our own group previously reported in a mouse model using nonmyeloablative conditioning that production of donor T cells is associated with donor-specific tolerance to skin allografts (25) . Notably, although myeloid chimerism was present at high levels, donor skin grafts were rejected. Similar findings were recently reported in a nonhuman primate model (Invited commentary, manuscript in press, Nature Reviews Nephrology 2012) (26) . Our clinical findings and these historic supporting studies have led us to use T-cell chimerism as our primary endpoint for decisions regarding immunosuppression weaning and withdrawal.
In summary, we report here the interim follow-up for 15 subjects who underwent transplantation with a bioengineered FC-based HSCT product. We have established durable macrochimerism in the majority of subjects treated with the target cell dose and conditioning, with PRA less than 20%, without GVHD or engraftment syndrome. The conditioning is well tolerated and can be managed as an outpatient. Studies are currently underway to adapt this approach to deceased donors in which a sequential or delayed tolerance approach would be necessary, and for subjects who have already had a living donor renal transplant and have a donor willing and able to donate HSCT (IND 14900: www.clinicaltrials.gov).
MATERIALS AND METHODS
All protocols were approved by the Northwestern University and University of Louisville Institutional Review Boards and the FDA (IDE 13947). Informed consent was obtained for all donors and recipients.
HSC or Kidney Conditioning Regimen
Conditioning consisted of three doses of fludarabine (30 mg/kg/dose) on days j4, j3, and j2; two doses of cyclophosphamide (50 mg/kg/dose) on days j3 and +3; and 200 cGy TBI on day j1 relative to the renal transplantation (day 0). Hemodialysis was performed 6 to 8 hr after the administration of fludarabine and cyclophosphamide to avoid toxicities of these agents. Tacrolimus (target trough concentrations 8Y12 ng/mL) and MMF (1 g orally twice daily if recipient weight G80 kg and 1.25 g twice daily if weight 980 kg) were started on day j3 and continued as maintenance immunosuppression. Kidney transplantation was performed without antibody induction therapy or oral corticosteroids. A bioengineered FDA-regulated HSC product enriched for facilitating cells (FCRx) was infused intravenously on the day following kidney transplantation.
